Once daily administration of the SGLT2 inhibitor, empagliflozin, attenuates markers of renal fibrosis without improving albuminuria in diabetic db/db mice

Blood glucose control is the primary strategy to prevent complications in diabetes. At the onset of kidney disease, therapies that inhibit components of the renin angiotensin system (RAS) are also indicated, but these approaches are not wholly effective. Here, we show that once daily administration...

Descripción completa

Detalles Bibliográficos
Autores principales: Gallo, Linda A., Ward, Micheal S., Fotheringham, Amelia K., Zhuang, Aowen, Borg, Danielle J., Flemming, Nicole B., Harvie, Ben M., Kinneally, Toni L., Yeh, Shang-Ming, McCarthy, Domenica A., Koepsell, Hermann, Vallon, Volker, Pollock, Carol, Panchapakesan, Usha, Forbes, Josephine M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2016
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4881020/
https://www.ncbi.nlm.nih.gov/pubmed/27226136
http://dx.doi.org/10.1038/srep26428

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4881020/
https://www.ncbi.nlm.nih.gov/pubmed/27226136
http://dx.doi.org/10.1038/srep26428

Ejemplares similares